CardioFocus

CardioFocus is an operating company, not an investment manager or family office. Capital-allocation and R&D-prioritization decisions sit with Chief Executive Officer Burke T. Barrett and the leadership team listed on the firm's website, which includes heads of Finance and Administration, Engineering, and Business Development. The board composition that governs those decisions is not publicly disclosed.

CardioFocus operates as a private medical-device company headquartered in Marlborough, Massachusetts. Public records show a history of equity and venture-style financings — including $55 million secured in May 2019 and $20 million in March 2017 (per the firm) — consistent with a venture-backed structure. It is not identified as a subsidiary of a larger pharmaceutical or device manufacturer.

The company originally gained FDA approval for its HeartLight laser-balloon ablation system in 2016 and treated more than 10,000 patients with that technology. Since 2024 it has pivoted almost entirely to pulsed field ablation (PFA), acquiring the electrophysiology division of Galvanize Therapeutics to bring in the Centauri generator and advancing three additional proprietary PFA catheters: QuickShot Nav, OptiShot, and the CardioWave system.

CardioFocus commercializes across the United States, Europe, and Japan. It maintains distribution partnerships with Japan Lifeline in Japan (per the firm, February 2025), BIOTRONIK for broader European access (per the firm, July 2025), and MicroPort CRM across Spain and Portugal. A February 2025 strategic alliance with Japan Lifeline indicates continued expansion in Asia.

Yes. In October 2025 CardioFocus announced a collaboration with Stereotaxis to advance robotic pulsed field ablation for cardiac arrhythmias. The partnership aims to integrate Stereotaxis's robotic magnetic navigation with CardioFocus's PFA catheters, targeting electrophysiology labs that already use robotic workflows.